Alvotech

Alvotech is a global biopharmaceutical company focused on the development, manufacture, and commercialisation of biosimilar medicines.

Founded in 2013, Alvotech is dedicated to enhancing access to high-quality biologics through its expertise in biosimilar development and manufacturing. Headquartered in Reykjavik, Iceland, the company operates state-of-the-art facilities and leverages cutting-edge technology to create cost-effective alternatives to branded biologic therapies. Alvotech aims to address the growing demand for affordable treatments while maintaining rigorous standards of quality, safety, and efficacy. Its integrated approach encompasses every stage of biosimilar development, from cell line creation and process development to commercial-scale production.

Key Products and Services

Biosimilar Portfolio: A robust pipeline of biosimilar candidates targeting therapeutic areas such as immunology, oncology, and ophthalmology.
Manufacturing Expertise: Advanced, vertically integrated manufacturing capabilities for high-quality biologics production.
Global Partnerships: Strategic alliances with leading pharmaceutical companies to ensure global distribution and market reach.
Research and Development: Innovative R&D efforts focused on developing biosimilar alternatives to some of the most widely used biologics worldwide.

Alvotech's mission is to improve patient access to affordable, life-changing treatments while fostering innovation in the biopharmaceutical industry. With a strong commitment to sustainability, compliance, and global collaboration, the company continues to build its reputation as a trusted partner in the field of biosimilar medicines.